Repligen Corporation
Repligen Corporation (RGEN) Financial Performance & Income Statement Overview
Access detailed quarterly and annual financial reports for Repligen Corporation (RGEN), covering cash flow, earnings, and balance sheets.
Repligen Corporation (RGEN) Income Statement & Financial Overview
View the income breakdown for Repligen Corporation RGEN across both annual and quarterly reports.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $169.17M | $167.55M | $154.87M | $154.07M |
| Cost of Revenue | $78.42M | $128.71M | $77.38M | $85.30M |
| Gross Profit | $90.76M | $38.84M | $77.49M | $68.77M |
| Gross Profit Ratio | $0.54 | $0.23 | $0.50 | $0.45 |
| R&D Expenses | $12.92M | $11.68M | $9.71M | $10.57M |
| SG&A Expenses | $71.25M | $56.63M | $73.94M | $64.70M |
| Operating Expenses | $84.18M | $120.95M | $85.32M | $75.27M |
| Total Costs & Expenses | $162.59M | $204.05M | $162.70M | $152.59M |
| Interest Income | $7.31M | -$411000.00 | $0.00 | $0.00 |
| Interest Expense | $5.66M | $5.46M | $0.00 | $5.50M |
| Depreciation & Amortization | $23.19M | $17.40M | $17.42M | $16.76M |
| EBITDA | $36.38M | $33.71M | $21.39M | $27.44M |
| EBITDA Ratio | $0.22 | $0.20 | $0.14 | $0.18 |
| Operating Income | $6.58M | -$36.50M | -$7.83M | $1.49M |
| Operating Income Ratio | $0.04 | -$0.22 | -$0.05 | $0.010 |
| Other Income/Expenses (Net) | $1.36M | -$2.11M | $6.68M | $3.69M |
| Income Before Tax | $7.94M | -$38.61M | -$1.15M | $5.18M |
| Income Before Tax Ratio | $0.05 | -$0.23 | -$0.007 | $0.03 |
| Income Tax Expense | $2.11M | -$4.74M | -$495000.00 | $1.86M |
| Net Income | $5.83M | -$33.87M | -$654000.00 | $3.32M |
| Net Income Ratio | $0.03 | -$0.20 | -$0.004 | $0.02 |
| EPS | $0.10 | -$0.60 | $0.32 | $0.06 |
| Diluted EPS | $0.10 | -$0.60 | $0.32 | $0.06 |
| Weighted Avg Shares Outstanding | $56.12M | $56.06M | $56.01M | $55.88M |
| Weighted Avg Shares Outstanding (Diluted) | $56.56M | $56.06M | $56.94M | $56.43M |
Financial performance has remained strong, with revenue growing from $154.07M in Q2 2024 to $169.17M in Q1 2025. Gross profit continued to perform well, with margins at 54% in the latest quarter. Operating income reached $6.58M in Q1 2025, holding a steady 4% margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at $36.38M. Net income rose to $5.83M, keeping EPS at $0.10. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan